Neuphoria Therapeutics (NEUP) Net Cash Flow (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Net Cash Flow of -$3.4 million for Q1 2026, down 126.95% year-over-year from $12.6 million in Q1 2025, and down 141.18% on a QoQ basis from $8.3 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Net Cash Flow data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 126.95% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 83.04% YoY) and the FY2025 annual result came in at $1.6 million, up 280.42% from the prior year.
- Net Cash Flow retreated to -$3.4 million in Q1 2026 per NEUP's latest filing, from $8.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $12.6 million in Q1 2025 and bottomed at -$4.7 million in Q3 2024.
- The 4-year median for Net Cash Flow is -$1.5 million (2024), against an average of $579288.7.
- The widest annual swing landed in 2024, when Net Cash Flow sank 306.38%; it then soared 915.67% in 2025.
- Tracing NEUP's Net Cash Flow over 4 years: stood at $1.7 million in 2023, then slumped by 306.38% to -$3.5 million in 2024, then jumped by 337.98% to $8.3 million in 2025, then sank by 141.18% to -$3.4 million in 2026.
- Per Business Quant, the three latest NEUP Net Cash Flow figures stand at -$3.4 million (Q1 2026), $8.3 million (Q4 2025), and -$541033.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | 8.23 Mn |
| Dec 31, 2025 | 8.23 Mn |
| Sep 30, 2025 | -541,033.00 |
| Sep 30, 2025 | -541,033.00 |
| Jun 30, 2025 | -2.88 Mn |
| Jun 30, 2025 | -2.88 Mn |
| Mar 31, 2025 | 12.62 Mn |
| Mar 31, 2025 | 12.62 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Sep 30, 2024 | -4.66 Mn |
| Jun 30, 2024 | 4.11 Mn |
| Jun 30, 2024 | 4.11 Mn |
| Mar 31, 2024 | -1.55 Mn |
| Mar 31, 2024 | -1.55 Mn |
| Dec 31, 2023 | 1.68 Mn |
| Dec 31, 2023 | 1.68 Mn |
| Sep 30, 2023 | -3.82 Mn |
| Sep 30, 2023 | -3.82 Mn |